Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.765 USD | -7.59% | +14.84% | +1.14% |
02:43pm | Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating | MT |
May. 06 | Transcript : Corvus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.14% | 93.66M | |
+20.88% | 46.81B | |
-1.35% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+10.87% | 26.06B | |
-19.75% | 19.13B | |
+31.55% | 12.39B | |
-0.06% | 12.08B | |
-0.18% | 11.96B |
- Stock Market
- Equities
- CRVS Stock
- News Corvus Pharmaceuticals, Inc.
- Corvus Pharmaceuticals : Mizuho Downgrades Corvus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $7